| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 02/26/2004 | CA2495383A1 Fused benzene derivative and use |
| 02/26/2004 | CA2494847A1 Enos mutants useful for gene therapy |
| 02/26/2004 | CA2494546A1 Substituted glycine derivatives for use as medicaments |
| 02/25/2004 | EP1391457A1 Substituted 2-Phenylbenzimidazoles and their use as PARP inhibitors |
| 02/25/2004 | EP1391456A1 2-iminoimidazole derivative (2) |
| 02/25/2004 | EP1391451A1 2-iminopyrrolidine derivates |
| 02/25/2004 | EP1391199A1 Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| 02/25/2004 | EP1390740A1 Methods and formulations for increasing the affinity of a 1? adenosine receptor ligands for the a 1? adenosine receptor |
| 02/25/2004 | EP1390543A2 New polynucleotides and polypeptides of the ifnalpha-17 gene |
| 02/25/2004 | EP1390403A2 Peptides derived from neural thread proteins and their medical use |
| 02/25/2004 | EP1390391A1 Transporters and ion channels |
| 02/25/2004 | EP1390363A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| 02/25/2004 | EP1390349A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| 02/25/2004 | EP1390348A1 5-cyano-1h-indole derivatives as antagonists of the interleukine-8 receptors |
| 02/25/2004 | EP1390080A1 Azo compounds for type i phototherapy |
| 02/25/2004 | EP1390057A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and method of use |
| 02/25/2004 | EP1390025A1 Coenzyme q and eicosapentaenoic acid (epa) |
| 02/25/2004 | EP1390023A2 Pharmaceutical salts |
| 02/25/2004 | EP1390013A2 Therapeutic treatments using the direct application of antimicrobial metal compositions |
| 02/25/2004 | EP1389970A2 Compositions and methods of double-targeting virus infections and cancer cells |
| 02/25/2004 | EP1300407B1 Carbamates derived from arylalkylamines |
| 02/25/2004 | EP1267902B1 Cosmetic use of hop and ornithine |
| 02/25/2004 | EP1222171B1 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 02/25/2004 | EP1210326B1 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/25/2004 | EP1165064B1 Novel inhibitors of formation of advanced glycation endproducts (age's) |
| 02/25/2004 | EP0946181B1 Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications |
| 02/25/2004 | CN1478087A Indolylmaleimide derivatives as protein kinase C inibitors |
| 02/25/2004 | CN1478084A Compounds useful in treatment of inflammatory diseases |
| 02/25/2004 | CN1478081A Substituted 2-znilino-benzimidazoles and use thereof as NHE-inhibitors |
| 02/25/2004 | CN1478080A Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
| 02/25/2004 | CN1477977A Compositions of N-(methy/ethy/aminocarbony/)-4-(3-methy/pheny/amino)-3-pyridy/sulfonamide and cyclic oligosaccharides |
| 02/25/2004 | CN1477976A Combination of GABA agonists and aldose reductase inhibitors |
| 02/25/2004 | CN1477975A Combination of GABA agonists and sorbitol dehydrogenase inhibitors |
| 02/25/2004 | CN1477967A Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 02/25/2004 | CN1477961A Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders |
| 02/25/2004 | CN1477960A EPA receptor inhibitors to treat rheumatoid arthritis |
| 02/25/2004 | CN1476877A Medicine for curing prostatosis and its preparation method |
| 02/25/2004 | CN1476863A Haigou shenlong pill |
| 02/25/2004 | CN1476849A Medicine composition for promoting blood circulation and removing stasis |
| 02/25/2004 | CN1139579C Isoxazolecarboxamide derivatives |
| 02/25/2004 | CN1139570C Inhibition of matrix metalloproteases by acetylene-containing compound |
| 02/25/2004 | CN1139396C Life essence-filling marrow-benefitting and kedney-invigorating Chinese medicine preparation |
| 02/25/2004 | CN1139380C Water based externally used cream containing nitroglycerin, and prepn method and use thereof |
| 02/24/2004 | US6696478 Compound targeted to protein kinase c enzyme |
| 02/24/2004 | US6696467 Quinoline derivatives |
| 02/24/2004 | US6696464 Triazolo-pyridines anti-inflammatory compounds |
| 02/24/2004 | US6696450 Serotonergic agents with long-acting in vivo effects |
| 02/24/2004 | US6696449 Control degradation of conencting tissue; cardiovascular disorders |
| 02/24/2004 | US6696445 Neuropeptide y receptor antagonists comprising heterocyclic nitrogen compounds and/or prodrugs used for prophylaxis of eating and cardiovascular disorders |
| 02/24/2004 | US6696437 Polymerase inhibitors comprising heterocyclic amides such as 2-pyridin-2-ylbenzimidazole-4-carboxamide, used for prophylaxis of neurodegenerative disorders, damage to hearts or brains, and as anticarcinogenic agents |
| 02/24/2004 | US6696427 Use of bisphosphonates for the prevention and treatment of infectious processes |
| 02/19/2004 | WO2004015058A2 Nephritis treatment by gene therapy |
| 02/19/2004 | WO2004014931A1 ARYL 5-THIO-β-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME |
| 02/19/2004 | WO2004014930A1 PROCESS FOR SELECTIVE PRODUCTION OF ARYL 5-THIO-β-D- ALDOHEXOPYRANOSIDES |
| 02/19/2004 | WO2004014920A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | WO2004014911A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | WO2004014903A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 02/19/2004 | WO2004014873A1 4-substituted quinazoline-8-carboxyamide derivative and pharmaceutically acceptable addition salt thereof |
| 02/19/2004 | WO2004014861A1 4-substituted-quinoline-8-carboxylic amide derivatives and pharmacologically acceptable addition salts thereof |
| 02/19/2004 | WO2004014844A2 Aryl and heteroaryl compounds and methods to modulate coagulation |
| 02/19/2004 | WO2004014842A1 Acylated arylcycloalkylamines and their use as pharmaceuticals |
| 02/19/2004 | WO2004014825A1 Cannabinoid receptor ligands |
| 02/19/2004 | WO2004014430A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | WO2004014425A1 Activators of small conductance calcium activated potassium channels and use thereof |
| 02/19/2004 | WO2004014414A1 Novel uses of rfrp and ot7t022 |
| 02/19/2004 | WO2004014398A1 The use of n-acetyl-d-glucosamine for preparing medicines for urogenital tract infection’s treatment and prevention |
| 02/19/2004 | WO2004014374A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/19/2004 | WO2004014372A1 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| 02/19/2004 | WO2004014369A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/19/2004 | WO2004014360A2 Pharmaceutical compositions for the treatment of urinary incontinence |
| 02/19/2004 | WO2004014352A2 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | WO2004007478A3 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 02/19/2004 | WO2004000840A3 Quinuclidine derivatives and pharmaceutical compositions containing the same |
| 02/19/2004 | WO2003097852A3 Assay for identifying inhibitors of fc gamma riii signaling |
| 02/19/2004 | WO2003086306A3 5ht2c receptor modulators |
| 02/19/2004 | WO2003070188A3 Method of treating trx mediated diseases |
| 02/19/2004 | WO2003065987A3 Granzyme b inhibitors |
| 02/19/2004 | WO2003065046A3 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| 02/19/2004 | WO2003024402A3 Lpa receptor agonists and antagonists and methods of use |
| 02/19/2004 | WO2003014731A3 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 02/19/2004 | WO2003013586B1 Access control system |
| 02/19/2004 | WO2002048337A3 Secreted human proteins |
| 02/19/2004 | US20040034229 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists |
| 02/19/2004 | US20040034105 Fewer side and/or analgesic effects |
| 02/19/2004 | US20040034090 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors |
| 02/19/2004 | US20040034084 Side effect reduction; for treatment of AIDS, cancer and arthritis |
| 02/19/2004 | US20040034076 Such as methyl-3-azido-2-((4,6-dimethoxy-2-pyrimidinyl)oxy) 3,3-diphenylpropionate; for treatment of high blood pressure |
| 02/19/2004 | US20040034070 Propanolaminotetralines, preparation thereof and compositions containing same |
| 02/19/2004 | US20040034066 Rosiglitazone hydrochloride is stable, water solubility, high melting point, bulk flow and good for bulk preparation and handling; salt formation |
| 02/19/2004 | US20040034065 A mixture of valsartan, an insulin secretion enhancer or a insulin sensitizer, for treating hypertension, congestive heart failure, diabetes, type 2 diabetes, renal failure, premenstrual syndrome, coronary heart disease |
| 02/19/2004 | US20040034046 Quinazoline derivatives |
| 02/19/2004 | US20040034040 E.g., 5-(4-(3-chloro-4-methoxybenzylamino)-5,6,7,8-tetra-hydro-1-benzothieno(2,3 -d) pyrimidin-2-yl)valeric acid to treat high pullmonary pressure; hypotensive agents; liver, cardiovascular, kidney and sexual disorders; antiallergens |
| 02/19/2004 | US20040034032 Quinoline and quinazoline compounds useful in therapy |
| 02/19/2004 | US20040034026 The use of a vasculostatic compound and a second active ingredient which decreases the activity of the epidermal growth factor (EGF); synergistic, angiogenesis inhibitors; antiproliferative agents; tyrosine kinase enzyme inhibitors |
| 02/19/2004 | US20040034018 2-amino-trihydroindole or tetrahydronapthalene-2-yl derivatives, useful for disease state associated with smooth muscle disorders, such as gastrointestinal and urogenital disorders |
| 02/19/2004 | US20040034017 4-fluoroalkyl-2h-benzopyrans anti-estogenic activity |
| 02/19/2004 | US20040034012 Superior arginine vasopressin receptor antagonism; a 6-membered aromatic ring having nitrogen at the 2-position there of is substituted at 2 position of the imidazobenzazepine ring |
| 02/19/2004 | US20040033993 Treatment of cardiovascular and related pathologies |
| 02/19/2004 | US20040033992 Treatment of cardiovascular and related pathologies |
| 02/19/2004 | US20040033991 Treating of cardiovascular and related pathologies |